No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials
Posted inCardiology news

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials

An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indications for beta blockade.
Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses
Posted inCardiology Clinical Updates news Specialties

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy considerations in contemporary practice.
Safety of Beta Blocker Withdrawal After Myocardial Infarction Without Reduced Ejection Fraction: Insights from the REBOOT Trial Post Hoc Analysis
Posted inCardiology news Specialties

Safety of Beta Blocker Withdrawal After Myocardial Infarction Without Reduced Ejection Fraction: Insights from the REBOOT Trial Post Hoc Analysis

Post hoc analysis of the REBOOT trial shows that withholding or withdrawing beta blockers after myocardial infarction in patients with preserved LVEF (>40%) does not increase short-term or recurrent ischaemic events, challenging current universal beta blocker recommendations.